ABCL Stock Analysis: Cheap Cash-Rich Biotech Bet?

AbCellera looks cheap for a reason, but the setup is finally getting interesting. ABCL stock analysis in April 2026 comes down to three facts: revenue snapped back to $75.1 million in 2025, the company still has roughly $700 million of available liquidity, and lead menopause program ABCL635 has a real catalyst window with Phase 1 …

Read more

CDNL Stock Analysis 2026: Great Business, Tougher Stock

CDNL stock analysis 2026: Cardinal Infrastructure is growing fast enough to get your attention, but the stock has already run hard enough that you need to be careful. Full-year 2025 revenue jumped 45% to $456.0 million, backlog reached a record $682 million, and 2026 guidance implies another huge step up. The problem is simpler: this …

Read more

Is FIRE Dead in 2026? The Math Got Harder

Is FIRE dead in 2026? No. But the easy version of FIRE is. For most people chasing financial independence, the math got harder over the last few years. Stocks are not cheap, healthcare is still a mess before Medicare, and Morningstar’s latest research says a new retiree who wants inflation-adjusted spending over 30 years should …

Read more